Selective Androgen Receptor Modulators (SARMs) were initially developed to address conditions like muscle wasting, osteoporosis, and other disorders associated with muscle and bone loss. The goal was to create compounds that could selectively target and activate androgen receptors in specific tissues, such as muscles and bones, while minimizing the impact on other organs, which is a common issue with traditional anabolic steroids.